Pelvic exenteration for recurrent endometrial adenocarcinoma a retrospective multi-institutional study about 21 patients

Vito Chiantera, Martina Rossi, Pierandrea De Iaco, Christardt Koehler, Simone Marnitz, Valerio Gallotta, Alessandro Pasquale Margariti, Fabio Parazzini, Giovanni Scambia, Achim Schneider, Giuseppe Filiberto Vercellino

Research output: Contribution to journalArticlepeer-review


Objective: The aim of our study was to evaluate morbidity, mortality, and long-term survival of patients who underwent pelvic exenteration (PE) with curative intent for recurrence of endometrial adenocarcinoma during a single decade. Methods: We defined a cohort of 21 patients who met our inclusion criteria, referred to 4 cooperating gynecologic oncology settings in Germany and Italy between 2000 and 2011.Data regarding surgery, histology, and oncologic outcomeswere collected and statistically evaluated. Survival was determined from the day of exenteration until the last follow-up or death. Results: The median age was 66 years. A total of 42.9% of the patients had major complications, and a complete resection was achieved in 85.7% of the patients. A total of 71.4% of the patients had negative nodes. No patient died intraoperatively. The perioperative mortality, calculated within 30 days from PE, was 4.8%. The overall 5-year survival rate, evaluated using the Kaplan-Meier method, was 40%. For the subgroup with complete resection and negative lymph nodes, overall survival reached 60%. Conclusions: Despite a high complication rate, PE for solitary pelvic recurrence of endometrial cancer yields a high rate of long-term survival.

Original languageEnglish
Pages (from-to)880-884
Number of pages5
JournalInternational Journal of Gynecological Cancer
Issue number5
Publication statusPublished - 2014


  • Morbidity
  • Pelvic exenteration
  • Recurrent endometrial cancer
  • Survival

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology
  • Medicine(all)


Dive into the research topics of 'Pelvic exenteration for recurrent endometrial adenocarcinoma a retrospective multi-institutional study about 21 patients'. Together they form a unique fingerprint.

Cite this